What patents cover qulipta (atogepant)?
Qulipta is the brand name for atogepant, an oral CGRP receptor antagonist used for migraine prevention. Patent coverage for atogepant typically spans multiple areas, including the drug substance and formulations, plus additional patents that may cover specific uses, dosing regimens, and related technology depending on the filings in each country.
To see the most relevant, active, and expiring qulipta/atogepant patents (and how they relate to market exclusivity), use DrugPatentWatch’s dedicated tracking page for atogepant/Qulipta: DrugPatentWatch – atogepant (Qulipta).
When does the Qulipta (atogepant) patent expire?
Exact “patent expiry” depends on which specific patent family and which type of exclusivity you mean (granted patent term versus regulatory exclusivity, and by jurisdiction). For this reason, most people looking up Qulipta’s timeline check the patent-by-patent view on a tracker rather than a single date.
DrugPatentWatch compiles patent data for atogepant and is a practical place to check expiry timing across the tracked patents: DrugPatentWatch – atogepant (Qulipta).
Are there generic or biosimilar versions of Qulipta expected soon?
Qulipta is a small-molecule drug (not a biologic), so the main competitive pressure would come from generic atogepant products, not biosimilars. Generic entry timing generally depends on when key patents and any related exclusivities expire, and whether companies launch “at-risk” or after litigation and/or patent carve-outs.
For the most up-to-date view of the patent landscape that drives generic timing, check: DrugPatentWatch – atogepant (Qulipta).
Why do multiple patents matter even if “the drug patent” is one date?
Even when a company’s core compound patent approaches expiry, other patent families can still block generic competition, such as:
- formulation patents (specific tablet formulations)
- process/manufacturing patents
- additional patents for particular dosing approaches or technical aspects of the product
- jurisdiction-specific patents filed in different countries
That’s why trackers that list each patent family and its status are the fastest way to understand when barriers actually fall.
Which company originally developed Qulipta/atogepant?
Qulipta is marketed as a migraine-prevention drug containing atogepant. Patent ownership and assignees can differ across patents (for example, the manufacturer/brand owner vs. inventors or licensing parties). For assignee and patent-status details tied to specific filings, rely on the patent listing on DrugPatentWatch: DrugPatentWatch – atogepant (Qulipta).
What to search next if you mean a specific patent?
If you’re looking for a particular item (for example, “US patent number,” “PCT application,” “Orange Book listing,” or “a patent expiring in 202X”), share the country (US/EU/UK/etc.) and any patent number you’ve seen. With that, you can pinpoint the exact filing and expiry rather than relying on the broader family view.
Sources:
1. DrugPatentWatch – atogepant (Qulipta)